Compared side by side
Thymalin vs thymogen: how they differ
The short answer
Thymogen is one piece of thymalin: thymalin is a peptide extract of calf thymus, and thymogen is the two-amino-acid peptide Glu-Trp that the same Russian group isolated from it and developed into an immune drug of its own. In mice thymogen slowed tumors through natural killer cells, and in human immune cells in the lab thymalin lowered inflammatory signals; a Russian placebo-controlled study found fewer complications after cancer surgery with thymogen. Tested independently in the US as IM862, thymogen did no better than placebo against Kaposi sarcoma, and almost all of thymalin’s research is by its developers.
Side by side
| Compared | Thymalin | Thymogen |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Timalin, Thymaline, Thymus peptide complex | Timogen, Glu-Trp, EW dipeptide, L-glutamyl-L-tryptophan, IM862 |
| What it is | A peptide extract of calf thymus from the Russian bioregulator program behind Epitalon, used as an immune drug. | A two-amino-acid peptide (Glu-Trp) from the Russian bioregulator program, isolated from the thymus extract Thymalin and used as an immune drug. |
| How it works | A peptide extract of calf thymus, one of the first two products of Vladimir Khavinson's St. Petersburg bioregulator program, used as an immune drug. Its active parts include two dipeptides the same group later made on their own: Lys-Glu (Vilon) and Glu-Trp (Thymogen). In human blood stem cells in the lab it pushed immature cells toward mature T cells, and in human immune cells it and its two dipeptides lowered the inflammatory signals IL-1β, IL-6 and TNF-α. In people, a study of 266 older adults followed for 6 to 8 years reported fewer deaths with it than in a control group, and in severe COVID-19 its developers report lower hospital mortality when it was added to basic therapy; neither study is described as randomized or blinded, and almost all of the work is by its developers. It is a different substance from thymulin and from thymosin alpha-1. | A dipeptide, Glu-Trp (EW), that Vladimir Khavinson's St. Petersburg group isolated from their calf-thymus extract Thymalin and developed into an immune drug. In mice, a US team found it slowed tumors only when natural killer cells were present, so it works through the immune system rather than on tumor cells directly. In rats injected for a year, the longest-lived tenth lived longer and tumors were fewer. In people, a Russian placebo-controlled study before abdominal cancer surgery reported fewer complications; tested independently in the US as IM862, it did no better than placebo against Kaposi sarcoma in a phase 3 trial of 202 people. |
| Commonly reported | Little to feel during a course; injection-site soreness is the usual complaint. | Little to feel during a short course; some soreness where it goes in. |
| Studied range | No study indexed on PubMed states or tests a dose of Thymalin: the amounts people run are their own protocol, not a reference. | No study has set a dose of Thymogen for the uses people run it for: the amounts people run are their own protocol, not a reference. |
| How often | Daily | Daily |
| Half-life | Unknown (never measured) | Unknown (never measured in people) |
| Route | IM injection, SubQ injection | SubQ injection, Nasal spray, IM injection |
| Typical run | Run in short courses rather than continuously, like the other bioregulators: commonly 5–10 days, repeated months later. In the long Russian follow-up study, courses were given during the first two to three years only. No study has tested a course length. | Run in short courses rather than continuously: the Russian surgical study gave it for 7 days, and community courses run 3–10 days. No study has tested a course length for general use. |
| Evidence | Emerging: primarily preclinical / limited human data | Emerging: primarily preclinical / limited human data |
| Common side effects | Injection-site pain or redness, firmness at the injection site | Injection-site redness or soreness, nasal irritation or sneezing (spray) |
- Category
- ThymalinHealing & recovery
- ThymogenHealing & recovery
- Also known as
- ThymalinTimalin, Thymaline, Thymus peptide complex
- ThymogenTimogen, Glu-Trp, EW dipeptide, L-glutamyl-L-tryptophan, IM862
- What it is
- ThymalinA peptide extract of calf thymus from the Russian bioregulator program behind Epitalon, used as an immune drug.
- ThymogenA two-amino-acid peptide (Glu-Trp) from the Russian bioregulator program, isolated from the thymus extract Thymalin and used as an immune drug.
- How it works
- ThymalinA peptide extract of calf thymus, one of the first two products of Vladimir Khavinson's St. Petersburg bioregulator program, used as an immune drug. Its active parts include two dipeptides the same group later made on their own: Lys-Glu (Vilon) and Glu-Trp (Thymogen). In human blood stem cells in the lab it pushed immature cells toward mature T cells, and in human immune cells it and its two dipeptides lowered the inflammatory signals IL-1β, IL-6 and TNF-α. In people, a study of 266 older adults followed for 6 to 8 years reported fewer deaths with it than in a control group, and in severe COVID-19 its developers report lower hospital mortality when it was added to basic therapy; neither study is described as randomized or blinded, and almost all of the work is by its developers. It is a different substance from thymulin and from thymosin alpha-1.
- ThymogenA dipeptide, Glu-Trp (EW), that Vladimir Khavinson's St. Petersburg group isolated from their calf-thymus extract Thymalin and developed into an immune drug. In mice, a US team found it slowed tumors only when natural killer cells were present, so it works through the immune system rather than on tumor cells directly. In rats injected for a year, the longest-lived tenth lived longer and tumors were fewer. In people, a Russian placebo-controlled study before abdominal cancer surgery reported fewer complications; tested independently in the US as IM862, it did no better than placebo against Kaposi sarcoma in a phase 3 trial of 202 people.
- Commonly reported
- ThymalinLittle to feel during a course; injection-site soreness is the usual complaint.
- ThymogenLittle to feel during a short course; some soreness where it goes in.
- Studied range
- ThymalinNo study indexed on PubMed states or tests a dose of Thymalin: the amounts people run are their own protocol, not a reference.
- ThymogenNo study has set a dose of Thymogen for the uses people run it for: the amounts people run are their own protocol, not a reference.
- How often
- ThymalinDaily
- ThymogenDaily
- Half-life
- ThymalinUnknown (never measured)
- ThymogenUnknown (never measured in people)
- Route
- ThymalinIM injection, SubQ injection
- ThymogenSubQ injection, Nasal spray, IM injection
- Typical run
- ThymalinRun in short courses rather than continuously, like the other bioregulators: commonly 5–10 days, repeated months later. In the long Russian follow-up study, courses were given during the first two to three years only. No study has tested a course length.
- ThymogenRun in short courses rather than continuously: the Russian surgical study gave it for 7 days, and community courses run 3–10 days. No study has tested a course length for general use.
- Evidence
- ThymalinEmerging: primarily preclinical / limited human data
- ThymogenEmerging: primarily preclinical / limited human data
- Common side effects
- ThymalinInjection-site pain or redness, firmness at the injection site
- ThymogenInjection-site redness or soreness, nasal irritation or sneezing (spray)
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Thymalin
- Day 1–10 A short course, then a long gap
- Day 10–60 What the studies measured after a course
- Day 60–365 The long study in older adults
Thymogen
- Day 1–7 A week-long course
- Day 7–30 What the surgery study measured
- Day 30–180 The independent trials said no
Together or one or the other
Thymalin and thymogen are a common stack: thymogen lists thymalin among its common stacks.
Community · Thymogen
The extract it came from
Thymogen is one of the active parts of Thymalin, and in Russian practice the two are sometimes used together for immune support. No study has tested the pair.
Questions people ask
How long do thymalin and thymogen last?
The half-life of thymalin is unknown (never measured). The half-life of thymogen is unknown (never measured in people).
How often are thymalin and thymogen taken?
Thymalin: daily. Routes: IM injection, subQ injection. Thymogen: daily. Routes: SubQ injection, nasal spray, IM injection.
How are thymalin and thymogen dosed in research?
The library carries no reference dose for thymalin. No study indexed on PubMed states or tests a dose of Thymalin: the amounts people run are their own protocol, not a reference. The library carries no reference dose for thymogen. No study has set a dose of Thymogen for the uses people run it for: the amounts people run are their own protocol, not a reference.
What are the common side effects of thymalin and thymogen?
For thymalin, the library lists: injection-site pain or redness, firmness at the injection site. For thymogen: injection-site redness or soreness, nasal irritation or sneezing (spray).
Are thymalin and thymogen taken together?
Thymalin and thymogen are a common stack: thymogen lists thymalin among its common stacks. Thymogen is one of the active parts of Thymalin, and in Russian practice the two are sometimes used together for immune support. No study has tested the pair.